Tardive dyskinesia (TD) is a movement disorder characterized by involuntary, repetitive movements, often affecting the face, tongue, or limbs, that can develop after long-term use of certain medications, especially antipsychotics. These symptoms can significantly impact daily life and quality of life for those affected.

Historically, treatment options were limited, but advances over the past decade have introduced new medication classes aimed specifically at reducing the severity of TD symptoms. Among these are drugs that block vesicular monoamine transporter 2 (VMAT2), which help regulate dopamine and other neurotransmitters involved in involuntary movement.

Tetrabenazine is one of the earliest VMAT2 inhibitors used in clinical practice, though it has a different approval status and evidence base compared with newer alternatives.

What Is Tetrabenazine?

Tetrabenazine is a medication that reduces the amount of certain neurotransmitters, including dopamine, in nerve cells by inhibiting VMAT2. It was first widely used for movement disorders and is FDA-approved for treating chorea associated with Huntington’s disease (not officially for tardive dyskinesia in the US).

While not FDA-approved specifically for TD, many clinicians have used tetrabenazine off-label to manage symptoms, especially when other options were unavailable or unsuitable. Early clinical reports and smaller studies suggest that it can reduce the severity of involuntary movements in some individuals with TD.

What Does the Research Say?

The scientific evidence for tetrabenazine’s effectiveness in TD is limited:

As per the research from National Library of Medicine, a small clinical trial reported that most patients experienced significant improvements in involuntary movement scores after weeks of tetrabenazine therapy, though one patient could not tolerate the drug due to sedation.

Systematic reviews highlight that, compared with newer VMAT2 inhibitors such as deutetrabenazine and valbenazine (both FDA-approved for TD), the data supporting tetrabenazine are weaker, and the trial designs vary widely.

Due to the limited size and quality of older studies, some experts consider tetrabenazine a third-line or off-label option when newer treatments are not appropriate.

It’s important to recognize that larger and more rigorous clinical trials have focused on newer VMAT2 inhibitors, which have clearer evidence and regulatory backing for treating tardive dyskinesia.

How Tetrabenazine Works?

Tetrabenazine’s mechanism involves reducing dopamine availability in brain synapses by impairing its storage in neuron vesicles. Because TD symptoms are thought to arise in part from dopamine receptor hypersensitivity following chronic dopamine-blocking medication use, lowering dopamine release may help calm abnormal movements.

However, this mechanism also means that tetrabenazine can influence mood and motor function broadly, which leads to both potential benefits and side effects.

Side Effects and Safety Considerations

Tetrabenazine has a broader side effect profile compared with the newer, FDA-approved VMAT2 inhibitors. Side effects reported in clinical use include:

Sedation or drowsiness

Parkinsonism-like symptoms (e.g., slowed movement)

Insomnia or restlessness

Mood changes such as depression

Research case reports from Dovepress and reviews also note that depression and suicidal thoughts have been linked to tetrabenazine use in some individuals, emphasizing the need for careful monitoring, especially in those with mood disorders.

Because of these potential effects, doctors typically monitor patients closely and may recommend alternative VMAT2 inhibitors that are generally better tolerated and have more robust evidence supporting their use.

Comparing Tetrabenazine to Newer VMAT2 Inhibitors

In recent years, two newer drugs — deutetrabenazine and valbenazine — have received FDA approval specifically for the treatment of tardive dyskinesia. These agents also target VMAT2 but have been tested in more rigorous clinical trials demonstrating safety and effectiveness in reducing TD symptoms.

Their longer duration of action and more predictable dosing make them preferred options in many treatment guidelines. Because of this, tetrabenazine is often reserved for situations where these newer agents are not available or are not suitable for a particular patient.

The Bottom Line for Patients

If you or a loved one is dealing with tardive dyskinesia, discussing treatment options with a qualified clinician is essential. While tetrabenazine has been used historically and may help some patients, it is generally considered an off-label or later-line approach due to limited high-quality evidence and a broader side effect profile.

Newer VMAT2 inhibitors that are FDA-approved for tardive dyskinesia — with clearer data on benefit and safety — may be more appropriate for many patients. A personalized conversation with your healthcare provider can help ensure that treatment decisions reflect your specific health needs and risk factors.

For more background on tardive dyskinesia and VMAT2 inhibitors, you can explore:

PubMed’s overview of approved medications for TD — a scholarly synthesis of medications studied in clinical settings.

National organization resources on tardive dyskinesia treatments — patient-focused summaries of therapy options.

Disclaimer: This article is intended for informational purposes only and does not replace medical advice from a qualified healthcare professional. Always consult your doctor before making decisions about medications or treatment.